Rho GTPase activating protein 44Genealiases: NPC-A-10 · RICH2
Q-omics provides the consensus-scored ARHGAP44 profile across patient tissues and cancer cell-line models. ARHGAP44 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ARHGAP44 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ARHGAP44 protein abundance shows 25,999 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, COAD, and GBM as cancer lineages where ARHGAP44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP44 survival associations across molecular data types. ARHGAP44 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP44 RNA expression–survival associations across cancer types. High ARHGAP44 expression shows unfavorable associations in LUSC, but favorable associations in MESO, SCLC, READ, LGG and PAAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ARHGAP44 RNA expression.
This table summarizes ARHGAP44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARHGAP44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP44 shows lower tumor expression in COAD, LUAD, KIRC, LUSC and UCEC and higher tumor expression in LIHC. The COAD box plot shows higher ARHGAP44 RNA expression in normal versus tumor tissue (log2 FC = −2.567, t-test p < 0.001).
This table shows molecular features associated with ARHGAP44 in patient tissues and cancer cell lines. In patient samples, ARHGAP44 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP44 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
